The Economic Burden of BRCA+ Metastatic Castration Resistant Prostate Cancer: Expert Perspective in LATAM Countries

Speaker(s)

Araujo L1, Tamayo C2, Góngora DS3, Meirelles IO4, Tabares MF5, Palma C6, López L7, Medina Y8, Ardila J8, de Oliveira R9
1Janssen-Cilag Farmacêutica Ltda, Sao Paulo, SP, Brazil, 2IQVIA LatAM, Bogotá, CUN, Colombia, 3IQVIA, Bogotá, CUN, Colombia, 4IQVIA, Real-World Insights, Brazil, Sao Paulo, Sao Paulo, Brazil, 5IQVIA, Real-World Insights, Argentina, Buenos Aires, Buenos Aires, Argentina, 6IQVIA, Real World Analytic Solutions & Real World Insights, Guatemala, Guatemala, Guatemala, Guatemala, 7IQVIA, Real-World Insights, Mexico, Mexico City, EM, Mexico, 8Janssen Pharmaceutical Companies of Johnson & Johnson, Bogotá D.C, CUN, Colombia, 9Janssen-Cilag Farmacêutica Ltda, São Paulo, Brazil

Presentation Documents

OBJECTIVES: Metastatic castration-resistant prostate cancer with BRCA mutations (BRCA+ mCRPC) is known for its poor prognosis and reduced overall survival. In LATAM, there is scarce evidence of disease-related economic burden. This study describes the resource use and direct costs of BRCA+ mCRPC in Argentina, Brazil, Colombia, Dominican Republic and Mexico.

METHODS: A pragmatic literature review was conducted to collect evidence on BRCA+ mCRPC management. Following the review, double-blinded, semi-structured, online interviews with medical experts (ten per country) were performed to collect data on healthcare resource use. Participants were from the private healthcare setting in Brazil and from public healthcare settings in other countries. Unit costs were obtained from official price lists and the results were reported with descriptive statistics and excluded pharmacological therapies.

RESULTS: 48 oncologists and 2 urologists were interviewed. Brazil and Colombia presented the highest proportion of tested patients (89% and 88%, respectively); while Mexico had the lowest proportion (57%). In the total annual cost of 1L and excluding pharmacological treatment costs, BRCA+ mCRPC patients presented an average direct cost of 50,624 USD in Argentina, 32,884 USD in Brazil, 5,928 USD in Colombia, 17,450 USD in Dominican Republic, and 13,463 USD in Mexico. In the second-line therapy, the average of total annual direct costs was 41,720 USD; 30,282 USD; 5,794 USD; 9,307 USD; and 14,365 USD, respectively. Supportive care represented the highest proportion of costs for both 1L and 2L in most countries, varying between 36%-68% in 1L and 38%-78% in 2L. Inpatient direct costs at least doubled between 1L and 2L in all countries (2.03-3.58-fold), with increasing number of hospitalized patients, length of stay and frequency on both hospitalizations and ICU.

CONCLUSIONS: There is a relevant burden of BRCA+ mCRPC patients in LATAM countries, with increased costs, need for supportive therapy and inpatient care.

Code

EE161

Topic

Economic Evaluation

Disease

Oncology, Personalized & Precision Medicine